Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer

Authors: Xueyan Dong, Guoqing Wang, Guoqing Zhang, Zhaohui Ni, Jian Suo, Juan Cui, Ai Cui, Qing Yang, Ying Xu, Fan Li

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Background

Gastric cancer is one of the most common malignant tumors in the world. Finding effective diagnostic biomarkers in urine or serum would represent the most ideal solution to detecting gastric cancer during annual physical examination. This study was to evaluate the potential of endothelial lipase (EL) as a urinary biomarker for diagnosis of gastric cancer.

Methods

The expression levels of EL was measured using Western blotting and immunohistochemical staining experiments on (tissue, serum, and urine) samples of gastric cancer patients versus healthy people. We also checked the EL levels in the urine samples of other cancer types (lung, colon and rectum cancers) and benign lesions (gastritis and gastric leiomyoma) to check if EL was specific to gastric cancer.

Result

We observed a clear separation between the EL expression levels in the urine samples of 90 gastric cancer patients and of 57 healthy volunteers. It was approximately 9.9 fold average decrease of the EL expression levels in the urine samples of gastric cancer compared to the healthy controls (P <0.0001), achieving a 0.967 AUC value for the ROC (receiver operating characteristic) curve, demonstrating it’s highly accurate as a diagnostic marker for gastric cancer. Interestingly, the expression levels of EL in tissue and serum samples were not nearly as discriminative as in urine samples (P = 0.90 and P = 0.79). In immunohistochemical experiments, positive expression of the EL protein was found in 67% (8/12) of gastric adjacent noncancerous and in 58% (7/12) of gastric cancer samples. There was no significant statistical in the expression levels of this protein between the gastric cancer and the matching noncancerous tissues (P =0.67).

Conclusions

The urinary EL as a highly accurate gastric cancer biomarker that is potentially applicable to the general screening with high sensitivity and specificity.

Virtual Slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​4527331618757552​
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C: Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009, 125: 666-673. 10.1002/ijc.24290.CrossRefPubMed
3.
Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol. 2009, 24: 37-41. 10.1111/j.1440-1746.2008.05753.x.CrossRefPubMed
4.
Jin J, Jin T, Quan M, Piao Y, Lin Z: Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol. 2012, 7: 135-10.1186/1746-1596-7-135.PubMedCentralCrossRefPubMed
5.
Ren J, Chen Z, Juan SJ, Yong XY, Pan BR, Fan DM: Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer. 2000, 88: 280-285. 10.1002/(SICI)1097-0142(20000115)88:2<280::AID-CNCR6>3.0.CO;2-7.CrossRefPubMed
6.
Xu Y, Zhang L, Hu G: Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals. 2009, 37: 18-25. 10.1016/j.biologicals.2008.08.002.CrossRefPubMed
7.
Kon OL, Yip TT, Ho MF, Chan WH, Wong WK, Tan SY, Ng WH, Kam SY, Eng A, Ho P: The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics. 2008, 1: 54-10.1186/1755-8794-1-54.PubMedCentralCrossRefPubMed
8.
Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006, 7: R80-10.1186/gb-2006-7-9-r80.PubMedCentralCrossRefPubMed
9.
Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR: Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009, 15: 1024-1031. 10.1158/1078-0432.CCR-08-1143.PubMedCentralCrossRefPubMed
10.
Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res. 2009, 16: 101-109.CrossRefPubMed
11.
Zavada J, Zavadova Z, Zat’ovicova M, Hyrsl L, Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 2003, 89: 1067-1071. 10.1038/sj.bjc.6601264.PubMedCentralCrossRefPubMed
12.
Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, Cartledge J, Thompson D, Selby PJ, Banks RE: Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer. 2009, 101: 1175-1182. 10.1038/sj.bjc.6605250.PubMedCentralCrossRefPubMed
13.
Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V: Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev. 2008, 17: 1034-1042. 10.1158/1055-9965.EPI-07-0365.CrossRefPubMed
14.
Yamaguchi T, Takahashi T, Yokota T, Kitamura K, Noguchi A, Kamiguchi M, Doi M, Ahn T, Sawai K, Yamane T: Urinary pepsinogen I as a tumor marker of stomach cancer after total gastrectomy. Cancer. 1991, 68: 906-909. 10.1002/1097-0142(19910815)68:4<906::AID-CNCR2820680438>3.0.CO;2-5.CrossRefPubMed
15.
Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow WH, Abnet CC: Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women’s health study. Cancer Epidemiol Biomarkers Prev. 2009, 18: 3075-3078. 10.1158/1055-9965.EPI-09-0680.PubMedCentralCrossRefPubMed
16.
Tsigris C, Karayiannakis AJ, Syrigos KN, Zbar A, Diamantis T, Kalahanis N, Alexiou D: Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res. 2002, 22: 3061-3065.PubMed
17.
Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, Ni Z, Zhang M, Kong X, Hoffman LL: An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res. 2010, 39: 1197-1207.PubMedCentralCrossRefPubMed
18.
Hong CS, Cui J, Ni Z, Su Y, Puett D, Li F, Xu Y: A computational method for prediction of excretory proteins and application to identification of gastric cancer markers in urine. PLoS One. 2011, 6: e16875-10.1371/journal.pone.0016875.PubMedCentralCrossRefPubMed
19.
Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T: Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 1999, 274: 14170-14175. 10.1074/jbc.274.20.14170.CrossRefPubMed
20.
Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ: A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999, 21: 424-428. 10.1038/7766.CrossRefPubMed
21.
Rader DJ, Jaye M: Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol. 2000, 11: 141-147. 10.1097/00041433-200004000-00006.CrossRefPubMed
22.
Annema W, Tietge UJ: Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011, 13: 257-265. 10.1007/s11883-011-0175-2.PubMedCentralCrossRefPubMed
23.
Yasuda T, Ishida T, Rader DJ: Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J. 2010, 74: 2263-2270. 10.1253/circj.CJ-10-0934.CrossRefPubMed
24.
Huang J, Qian HY, Li ZZ, Zhang JM, Wang S, Tao Y, Gao YL, Yin CQ, Que B, Sun T: Role of endothelial lipase in atherosclerosis. Transl Res. 2010, 156: 1-6. 10.1016/j.trsl.2010.05.003.CrossRefPubMed
25.
Wu X, Huang H, Tang F, Le K, Xu S, Liu P: Regulated expression of endothelial lipase in atherosclerosis. Mol Cell Endocrinol. 2010, 315: 233-238. 10.1016/j.mce.2009.11.003.CrossRefPubMed
26.
Takasu S, Mutoh M, Takahashi M, Nakagama H: Lipoprotein lipase as a candidate target for cancer prevention/therapy. Biochem Res Int. 2012, 2012: 398697-PubMedCentralCrossRefPubMed
27.
Lu J, Li J, Ji C, Yu W, Xu Z, Huang S: Expression of lipoprotein lipase associated with lung adenocarcinoma tissues. Mol Biol Rep. 2008, 35: 59-63. 10.1007/s11033-006-9053-3.CrossRefPubMed
28.
Nielsen JE, Lindegaard ML, Friis-Hansen L, Almstrup K, Leffers H, Nielsen LB, Rajpert-De Meyts E: Lipoprotein lipase and endothelial lipase in human testis and in germ cell neoplasms. Int J Androl. 2004, 33: e207-e215.CrossRef
29.
Haraldsson B, Sorensson J: Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci. 2004, 19: 7-10.PubMed
30.
Griffon N, Jin W, Petty TJ, Millar J, Badellino KO, Saven JG, Marchadier DH, Kempner ES, Billheimer J, Glick JM, Rader DJ: Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation. J Biol Chem. 2009, 284: 23322-23330. 10.1074/jbc.M109.037002.PubMedCentralCrossRefPubMed
31.
Parks SK, Chiche J, Pouyssegur J: pH control mechanisms of tumor survival and growth. J Cell Physiol. 2011, 226: 299-308. 10.1002/jcp.22400.CrossRefPubMed
32.
Demirag GG, Sullu Y, Gurgenyatagi D, Okumus NO, Yucel I: Expression of plakophilins (PKP1, PKP2, and PKP3) in gastric cancers. Diagn Pathol. 2011, 6: 1-10.1186/1746-1596-6-1.PubMedCentralCrossRefPubMed
33.
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS: Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011, 25: 1517-1524.PubMed
34.
Zhao J, Zhang X, Xin Y: Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 2011, 26: 1111-1120.PubMed
Metadata
Title
The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer
Authors
Xueyan Dong
Guoqing Wang
Guoqing Zhang
Zhaohui Ni
Jian Suo
Juan Cui
Ai Cui
Qing Yang
Ying Xu
Fan Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-45

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Research

An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas

Short report

Lack of SF3B1 R625 mutations in cutaneous melanoma

Methodology

An alternative high output tissue microarray technique

Research

Histological subtypes and characteristic structures of HPV-associated oropharyngeal carcinoma; study with Japanese cases

Retraction Note

Retraction Note: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco

Case Report

Concurrent malignant melanoma and cutaneous involvement by classical hodgkin lymphoma (CHL) in a 63 year-old man